IM Cannabis Announces Intention to Complete 30:1 Share Consolidation to Support Nasdaq Minimum Bid Price Compliance
Rhea-AI Summary
IM Cannabis (Nasdaq: IMCC) has approved a 30-for-1 consolidation of its issued and outstanding common shares (the “Consolidation”). One post-consolidated share will be issued for every thirty pre-consolidated shares. The Board expects the effective date to be August 27, 2026, with authority to effect it on or before September 15, 2026.
According to IM Cannabis, post-Consolidation shares are expected to be reduced from 18,117,650 to approximately 603,922, subject to rounding. No fractional shares will be issued; fractions of at least one-half will be rounded up, others cancelled. The new CUSIP and ISIN will be 44969Q505 and CA44969Q5059. The company states the primary purpose is to increase the per-share trading price to support regaining compliance with Nasdaq’s US$1.00 minimum bid price requirement, for which IM Cannabis has until October 6, 2026, though it cautions there is no assurance the action will restore compliance.
Positive
- 30:1 share consolidation approved to support Nasdaq bid price compliance
- Outstanding shares expected to drop from 18,117,650 to about 603,922
- New higher per-share price may help meet Nasdaq US$1.00 bid threshold
Negative
- Company has Nasdaq minimum bid price deadline of October 6, 2026
- No assurance consolidation will restore or maintain Nasdaq listing compliance
- Shareholders will face reduced liquidity with only about 603,922 shares outstanding post-consolidation
News Explained
The 30-for-1 consolidation will also proportionately adjust the exercise or conversion prices and share counts under outstanding convertible securities, resetting those instruments to the post-consolidation share structure.
Market reaction after 30:1 share consolidation: IMCC -5.15%
Following this news, IMCC has declined 5.15%, reflecting a notable negative market reaction. Argus tracked a trough of -20.7% from its starting point during tracking. Our momentum scanner has triggered 15 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $0.10. Trading volume is very high at 3.4x the average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 17 | Asset sale agreement | Positive | -12.5% | Agreement transferred European-focused assets while reducing liabilities and improving shareholders’ equity. |
| Aug 13 | 2Q26 earnings report | Negative | -6.2% | Revenue declined while operating and net losses widened during the first half. |
| Aug 07 | Convertible note financing | Negative | +4.3% | Convertible debt and warrants provided financing but introduced share issuance and dilution exposure. |
| Jul 27 | Board resignation update | Neutral | +1.3% | Director Alon Dayan resigned from the board for personal reasons. |
| Jul 01 | Convertible note financing | Negative | -1.4% | Convertible financing supplied proceeds while adding warrants and potential common-share issuance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Negative earnings and financing announcements aligned with declines, while the asset-sale and August convertible-financing announcements diverged from their measured reactions.
Key Terms
cusip financial
isin financial
minimum bid price requirement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
The Board has authorized the Consolidation to be effected on or before September 15, 2026, with the Company currently expecting August 27, 2026 to be the effective date of the Consolidation (the "Effective Date"). The Company anticipates that the Common Shares will begin trading on the Nasdaq Capital Market ("Nasdaq") on a post-Consolidation basis at the opening of trading on August 27, 2026, subject to final confirmation from Nasdaq and completion of applicable corporate, transfer agent and market implementation processes.
Upon the completion of the Consolidation, the CUSIP and ISIN of the Common Shares will be changed to 44969Q505 and CA44969Q5059, respectively. The Company's name and existing stock symbol "IMCC" will remain unchanged.
After giving effect to the Consolidation, the issued and outstanding Common Shares are expected to be reduced from 18,117,650 Common Shares to approximately 603,922 Common Shares, subject to rounding for fractional Common Shares. No fractional Common Shares will be issued in connection with the Consolidation. Instead, all fractional Common Shares equal to or greater than one-half resulting from the Consolidation will be rounded to the next whole number, otherwise, the fractional Common Share will be cancelled. The exercise price and/or conversion price and number of Common Shares issuable under any of the Company's outstanding convertible securities will be proportionately adjusted in connection with the Consolidation.
The primary purpose of the Consolidation is to increase the per-share trading price of the Common Shares in an effort to support the Company's efforts to regain compliance with Nasdaq's
Registered shareholders as of the Effective Date will receive a letter of transmittal from Computershare Investor Services Inc., the Company's registrar and transfer agent for its Common Shares, providing instructions for the exchange of their Common Shares as soon as practicable following the Effective Date. Registered shareholders may also obtain a copy of the letter of transmittal by accessing the Company's SEDAR+ profile at www.sedarplus.ca. Until surrendered, each share certificate or direct registration system statement representing pre-consolidated Common Shares will represent the number of whole post-consolidated Common Shares to which the holder is entitled as a result of the Consolidation. No action is required by beneficial holders to receive post-consolidation Common Shares in connection with the Consolidation. Beneficial shareholders who hold their Common Shares through intermediaries (e.g., a broker, bank, trust company, investment dealer or other financial institution) and who have questions regarding how the Consolidation will be processed should contact their intermediaries with respect to the Consolidation.
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) is an international company focused on building and scaling innovative businesses and technologies across global markets. The Company currently operates a medical cannabis platform serving patients in Israel and Germany while evaluating opportunities to expand into additional technology-driven sectors.
The IMC ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies and online platforms in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking information and forward-looking statements within the meaning of applicable Canadian and United States securities laws (collectively, "forward-looking statements"). Forward-looking statements are based on expectations, estimates, projections and interpretations as at the date of this press release and are often, but not always, identified by words and phrases such as "anticipate", "believe", "expect", "intend", "may", "plan", "should", "will", "would", "could", "estimate", "target", "subject to", "scheduled", "currently expects" and similar words or expressions.
Forward-looking statements in this press release include, without limitation, statements regarding the Consolidation, including the expected completion of the Consolidation, the Consolidation ratio, the expected Effective Date, the anticipated date on which the Common Shares will begin trading on a post-Consolidation basis on Nasdaq, the expected change to the CUSIP and ISIN numbers of the Common Shares, the expected number of Common Shares outstanding following completion of the Consolidation, the treatment of fractional Common Shares, proportionate adjustments to the exercise price and/or conversion price and number of Common Shares issuable under outstanding convertible, exchangeable or exercisable securities of the Company, the Company's expectation that the Consolidation will increase the per-share trading price of the Common Shares, the Company's intention and ability to regain compliance with Nasdaq's US
Forward-looking statements are based on a number of assumptions, including, without limitation, that the Consolidation will be completed on the anticipated terms and timeline; that all required corporate, regulatory, Nasdaq, DTC, transfer agent and other confirmations, approvals, filings, notices or processes will be obtained, made or completed when expected; that the Common Shares will begin trading on a post-Consolidation basis on Nasdaq on the anticipated date; that the Consolidation will result in an increase in the per-share trading price of the Common Shares; that the trading price of the Common Shares will be sufficient for the Company to regain compliance with Nasdaq's US
Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or developments to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, without limitation: the risk that the Consolidation may not be completed on the anticipated timeline or at all; the risk that required confirmations, approvals, filings, notices or processes may be delayed, withheld, conditional or not completed as expected; the risk that the Common Shares may not begin trading on a post-Consolidation basis on the anticipated date; the risk that the Consolidation may not result in a sustained increase in the per-share trading price of the Common Shares; the risk that the Company may not regain or maintain compliance with Nasdaq's US
Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management as of such date. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Company Contacts:
Michal Efraty
Investor & Public Relations
IM Cannabis Corp.
michal@efraty.com
Oren Shuster, Chief Executive Officer
IM Cannabis Corp.
info@imcannabis.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/im-cannabis-announces-intention-to-complete-301-share-consolidation-to-support-nasdaq-minimum-bid-price-compliance-302854493.html
SOURCE IM Cannabis Corp.